• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Carfilzomib
    1 Drug classified under this active ingredient

    All the Active Ingredient Drugs

    partial basket chart

    Proteasome Inhibitor. Carfilzomib 60 mg/vial.
    SINGLE DOSE VIALS (lyophilized cake/pwdr. for reconst.): 1×10,30,60 mg. Monother.: IV as a 10-min. infus. in cycles 1 through 12, admin. Carfilzomib days 1, 2, 8, 9, 15 and 16 of each 28-day cycle, see lit. From cycle 13, administer on days 1, 2, 15 and 16 of each 28-day cycle. Premedicate with dexamethasone 4 mg orally or intravenously 30 minutes to 4 hours before each dose in Cycle 1, then as needed to minimize infusion-related reactions. The recommen. start. dose is 20 mg/m2 in cycle 1 on days 1 and 2. If tolerated, incr. the dose to 27 mg/m2 on day 8 of Cycle 1 and thereafter. Continue until disease progression or unacceptable toxicity. For comb. with Dexamethasone, comb. with Lenalidomide and dexamethasone comb. with daratumumab and dexamethasone: See lit..
    For the tmt. of pts. with relapsed or refract. multiple myeloma who have received one to three prior lines of ther. In comb. with dexamethasone or with lenalidomide plus dexamethasone or daratumumab and dexamethasone. As a single agent for the tmt. of pts. with multiple myeloma who have received at least two prior therapies includ. bortezomib and an immunomodulat. agent and have demonstr. dis. progres. on or within 60 d. of completion of the last ther. Approval is based on response rate. Clinical benefit, such as improv. in survival or sympt., has not been verified.
    C/I: Hypersens.